Patent intelligence · US
US 12252550
Antibodies that bind to C1S and uses thereof
Antibodies that bind to C1S and uses thereof
Patent details — US 12252550
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 18, 2025
- Expiration
- Mar 13, 2045
- Applicant
- DIANTHUS THERAPEUTICS OPCO, INC.
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61P, A61P7/00
Quick answer
US 12252550 (Antibodies that bind to C1S and uses thereof) is held by DIANTHUS THERAPEUTICS OPCO, INC.. Status: granted. Granted Mar 18, 2025. Expires Mar 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DIANTHUS THERAPEUTICS OPCO, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61P, A61P7/00
More from DIANTHUS THERAPEUTICS OPCO, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12252550?
US 12252550 (Antibodies that bind to C1S and uses thereof) is held by DIANTHUS THERAPEUTICS OPCO, INC.. Status: granted. Granted Mar 18, 2025. Expires Mar 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12252550?
DIANTHUS THERAPEUTICS OPCO, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 12252550 expire?
Our index shows an expiration date of Mar 13, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.